Apostle Inc Announces Acceptance Into the StartX Accelerator Program
Apostle Inc is pleased to announce it’s been accepted into the prestigious StartX accelerator program. StartX is a renowned educational non-profit that accelerates the development of Stanford's top entrepreneurs through experiential education and collective intelligence. The acceptance rate has been between 8%-10%.
Menlo Park, CA, May 05, 2018 --(PR.com)-- Apostle Inc is pleased to announce it’s been accepted into the prestigious StartX accelerator program.
StartX is a renowned educational non-profit that accelerates the development of Stanford's top entrepreneurs through experiential education and collective intelligence. StartX alumni and trusted expert judges review and determine which teams are accepted. The acceptance rate has been between 8%-10%.
Apostle is selected into the StartX Accelerator Program (Summer 2018 session), following one initial review, four interviews and due diligence. The Stanford-StartX Fund (SSF), co-founded by StartX, Stanford University, and Stanford Health Care is available only to StartX companies with a Stanford-affiliated founder.
For more information about the StartX accelerator program, visit https://startx.com/accelerator.
About Apostle Inc
Apostle Inc is a biotechnology company in Menlo Park, CA. It’s in the business of the research, development, licensing, and sales of novel technologies, and the related intellectual properties, products, and services for diagnosis and treatment of human diseases, to fundamentally improve the accuracy and efficiency of liquid biopsy - the testing of circulating free DNA (cfDNA) - in early cancer detection or other clinical applications such as noninvasive prenatal testing (NIPT), tests for infectious diseases, therapeutics including CAR-T.
More information can be found at www.apostlebio.com.
Contact: info@apostlebio.com
StartX is a renowned educational non-profit that accelerates the development of Stanford's top entrepreneurs through experiential education and collective intelligence. StartX alumni and trusted expert judges review and determine which teams are accepted. The acceptance rate has been between 8%-10%.
Apostle is selected into the StartX Accelerator Program (Summer 2018 session), following one initial review, four interviews and due diligence. The Stanford-StartX Fund (SSF), co-founded by StartX, Stanford University, and Stanford Health Care is available only to StartX companies with a Stanford-affiliated founder.
For more information about the StartX accelerator program, visit https://startx.com/accelerator.
About Apostle Inc
Apostle Inc is a biotechnology company in Menlo Park, CA. It’s in the business of the research, development, licensing, and sales of novel technologies, and the related intellectual properties, products, and services for diagnosis and treatment of human diseases, to fundamentally improve the accuracy and efficiency of liquid biopsy - the testing of circulating free DNA (cfDNA) - in early cancer detection or other clinical applications such as noninvasive prenatal testing (NIPT), tests for infectious diseases, therapeutics including CAR-T.
More information can be found at www.apostlebio.com.
Contact: info@apostlebio.com
Contact
Apostle Inc
David Ge
650-483-5437
apostlebio.com
David Ge
650-483-5437
apostlebio.com
Contact
Categories